share_log

Brain Scientific Sees Increased First-Quarter Sales Momentum and Revenue Growth

Brain Scientific Sees Increased First-Quarter Sales Momentum and Revenue Growth

Brain Scientific认为第一季度销售势头增强,收入将增长
GlobeNewswire ·  2023/02/28 10:20

A significant order from a high-tech robotics company highlights growing interest in Piezo Motion's new series of piezomotors. Additional orders for the Company's new ferrous-free (non-magnetic) high torque motor underscores its suitability in medical MRI robotics applications.

一家高科技机器人公司的巨额订单突显出人们对Piezo Motion的新系列压电式电机的兴趣日益浓厚。该公司新的无铁(无磁)高扭矩电机的更多订单突显了其在医用核磁共振机器人应用中的适用性。

LAKEWOOD RANCH, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Piezo Motion, a Florida-based Brain Scientific (OTCQB:BRSFD) technology company, announces today increased demand for its new range of novel miniature rotary piezomotors (the RAS Series). The highly precise yet very affordable RAS motor is finding use in a growing range of applications including photonics, medical devices and miniature pumps. 

佛罗里达州莱克伍德牧场,2023年2月28日(环球通讯社)通过InvestorWire--总部位于佛罗里达州的Brain Science(OTCQB:BRSFD)的Piezo Motion一家科技公司今天宣布,对其新型微型旋转式压电机(TheRAS系列)。高精度但非常实惠的RAS电机正在越来越多的应用中使用,包括光电子、医疗设备和微型水泵。

"We just received our largest order to date for our new miniature motor from a hi-tech company that is working in the photonics space," said Dr. Mark Broderick, president of Piezo Motion. "It really was just a matter of time before our RAS motor started to get the attention it really deserves."

Piezo Motion的总裁博士马克·布罗德里克说:“我们刚刚从一家致力于光电子领域的高科技公司收到了迄今为止最大的一笔微型电机订单。”“我们的RAS发动机开始得到应有的关注只是个时间问题。”

Another significant development with Piezo Motion is the growing interest in our new and completely ferrous-free (non-magnetic) high-torque motor. The company received an order from the University of Hawaii and is also collaborating under contract with a US-based designer of medical robotics; both these applications are applying our non-magnetic motor within the field of medical MRI where traditional motors cannot operate.

Piezo Motion的另一个重大发展是人们对我们的新型、完全无铁(非磁性)高扭矩电机的兴趣与日俱增。该公司收到了夏威夷大学的订单,并与一家总部位于美国的医疗机器人设计师签订了合同;这两项应用都是将我们的非磁性电机应用于传统电机无法运行的医学核磁共振领域。

Along with these large orders, the company reported that a number of entrepreneurs and innovators are doing incredible things with Piezo Motion's innovative motors. For example, Reuben Brewer, an SRI employee, robotics-class professor at Stanford, and a home robotics lab mad scientist-type said, "I've tried out the new motor (RAS), and I love it! It has a very respectable torque, is reliable and a great price compared to alternative and bulkier traditional motors."

除了这些大订单,该公司还报告说,一些企业家和创新者正在用Piezo Motion的创新电机做令人难以置信的事情。例如,SRI员工、斯坦福大学机器人学教授鲁本·布鲁尔和家庭机器人实验室疯狂科学家类型的鲁本·布鲁尔说:“我试过这种新的电机(RAS),我喜欢它!它有非常可观的扭矩,可靠,与替代的、更笨重的传统电机相比,价格也很划算。”

Piezo Motion's technologies, which are protected by 27 worldwide patents, are applicable to a vast array of diversified markets including:

Piezo Motion的技术受到27项全球专利的保护,适用于广泛的多元化市场,包括:

  • Life science
  • Medical devices
  • Robotics
  • Aerospace
  • Semiconductor
  • Optics
  • Automotive systems 
  • 生命科学
  • 医疗器械
  • 机器人学
  • 航空航天
  • 半导体
  • 光学
  • 汽车系统

"Our piezo motors are filling a unique gap in the market. They are tiny, energy-efficient and precise, yet extremely affordable, finally allowing device manufacturers to use piezoelectric motors for large-scale manufacturing," said Hassan Kotob, chairman and CEO of Piezo Motion.

Piezo Motion董事长兼首席执行官哈桑·科托布表示:“我们的压电电机正在填补市场上一个独特的空白。它们体积小、节能、精度高,但价格极其实惠,最终使设备制造商能够使用压电电机进行大规模制造。”

About Piezo Motion

关于Piezo Motion

Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today's global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.

Brain Science旗下的Piezo Motion(Piezomotion.com)是精密电机技术的领先者,在研发负担得起的压电式电机方面投资数百万美元,以满足并超越当今全球市场的需求。该公司致力于开发创新技术和运动产品,以增强多种应用的功能。该公司与来自世界各地的初创企业、原始设备制造商、研究机构和工业公司合作,为他们产品背后的远见卓识者赋权。

About Brain Scientific

关于脑科学

Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap™ and NeuroEEG™ are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific's corporate strategy, products or investor relations, please visit brainscientific.com.

Brain Science是一家拥有多项专利和FDA批准产品的医疗技术公司。Brain Science致力于开发下一代解决方案,以推动神经诊断和OEM医疗设备的未来。Brain Science有两个产品线,涵盖神经学和精密运动。NeuroCap™和NeuroEEG™是智能神经诊断设备,可简化管理、缩短扫描时间并降低成本。Piezo Motion产品线由超高效紧凑型精密电机组成,将驱动下一代医疗设备。欲了解有关Brain Science公司的公司战略、产品或投资者关系的更多信息,请访问:brainScience fi.com。

Forward-Looking Statements

前瞻性陈述

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company's future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company's inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company's inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company's raw materials; and the failure to implement the company's business plans or strategies. Some of these and other factors are identified and described in more detail in the company's filings with the SEC. The company does not undertake to update these forward-looking statements.

本新闻稿中包含的任何不描述历史事实的陈述都可能构成前瞻性陈述。前瞻性陈述可能包括但不限于以下陈述:(I)未来业务的管理计划和目标,包括与脑电产品和服务以及压电电机技术的设计、开发和商业化有关的计划或目标;(Ii)收入(包括收入/亏损)、每股收益(包括收益/亏损)、资本支出、股息、资本结构或其他财务项目的预测;(Iii)公司未来的财务表现;(Iv)Piezo Motion与Brain Science的成功整合;以及(V)以上第(I)、(Ii)、(Iii)或(Iv)点所述任何陈述所依据的或与之有关的假设。此类前瞻性陈述不是为了预测或保证实际结果、业绩、事件或情况,也可能无法实现,因为它们是基于公司目前的预测、计划、目标、信念、预期、估计和假设,受许多风险、不确定性和其他影响的影响,其中许多是公司无法控制的。由于这些风险和不确定性,某些事件和情况的实际结果和时间可能与前瞻性陈述中描述的大不相同。可能影响或导致前瞻性陈述不准确或导致实际结果与预期或期望结果大不相同的因素可能包括但不限于, 该公司无法获得更多融资;与开发产品和相关产品相关的时间和资源过长;现金流不足和由此导致的流动性不足;该公司无法扩大其业务;政府对医疗器械和医疗保健行业的监管力度较大;缺乏产品多元化;该公司原材料价格波动;以及未能实施该公司的业务计划或战略。在该公司提交给美国证券交易委员会的文件中,对其中一些因素以及其他一些因素进行了识别和更详细的描述。该公司不承诺更新这些前瞻性陈述。

CONTACTS

触点

INVESTORS
ir@brainscientific.com

投资商
邮箱:ir@brainScience fic.com

MEDIA
pr@brainscientific.com

媒体
电子邮箱:pr@brainScience fic.com

Corporate Communications

企业通信

IBN (InvestorBrandNetwork)
Los Angeles, California
310.299.1717 Office
Editor@InvestorBrandNetwork.com

IBN(InvestorBrandNetwork)
加利福尼亚州洛杉矶
310.299.1717办公室
邮箱:EDITOR@InvestorBrandNetwork.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发